American Academy of Ophthalmology Annual Meeting 2017
Dr Monés participates at the Investigator Meetings of the principal clinical trials for AMD at AAO 201704/12/2017 · News
The Medical Director of the Institut de la Màcula, Jordi Monés, has played an active role at the Annual Congress of the American Academy of Ophthalmology (AAO), which was held in New Orleans in November. During this four-day long meeting of global importance, Dr. Monés took part in the Brolucizumab (Novartis) Advisory Board and that of Kodiak Sciences. Among his other activities, he was involved in the Investigator Meetings of LAMPA and PROXIMA (Roche).
On 9 November, the results obtained to week 48 in the Harrier (RTH28) clinical trial were presented at AAO2017. Harrier aims to compare the effectiveness and safety of brolucizumab with aflibercept (Eylea) in patients with exudative AMD. Apart from displaying a safety profile comparable to that of aflibercept at week 48, brolucizumab is attaining the goal of the drug’s non-inferiority when it is administered every 12 weeks after the loading phase. The study lasts 96 weeks and it will be necessary to await the next data analysis before the definitive results can be assessed.
With regard to Chroma, one of the two phase III studies to assess the safety and effectiveness of lampalizumab (an investigational medicinal product for the treatment of geographic atrophy secondary to AMD), this has not attained its principal aim. According to the data from Spectri (the other phase III study) presented at AAO2017, as was reported in September 2017, lampalizumab did not reduce the average change in the geographic atrophy (GA) lesion area compared to the simulated treatment at 1 year (48 weeks). The safety profile was in line with previous lampalizumab trials. On the basis of all the data from Chroma y Spectri, Roche will not apply for marketing approval for lampalizumab in AG.
The Annual Meeting of the AAO is one of the world‘s most important events in the field of ophthalmology. It gathers top-notch specialists to report and share developments in the research of a variety of ocular pathologies. The American Academy of Ophthalmology is the largest association in the country for ophthalmologists and professionals of the discipline. Together with over 90% of American doctors, the AAO also boasts 7,000 international associates.Intravitreal injectionsDry or atrophic AMDExudative or wet AMD